Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study

Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer

(2022) Jashodeep Datta et al.   GASTROENTEROLOGY

Multimodality Therapy in Operable Pancreatic Cancer: Should We Sequence Surgery Last?

(2021) Jashodeep Datta et al.   ANNALS OF SURGICAL ONCOLOGY

Inhibition of Hedgehog signaling alters fibroblast composition in pancreatic cancer

(2021) Nina G Steele et al.   CLINICAL CANCER RESEARCH

Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma

(2021) James S. Strong et al.   AMERICAN SURGEON

Targeting tumor-stromal IL-6/STAT3 signaling through IL-1 receptor inhibition in pancreatic cancer

(2021) Austin R Dosch et al.   MOLECULAR CANCER THERAPEUTICS

Pancreatic cancer stroma: an update on therapeutic targeting strategies

(2020) Abdel N. Hosein et al.   Nature Reviews Gastroenterology & Hepatology

Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer

(2019) Francis I. Macedo et al.   ANNALS OF SURGERY

Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts

(2019) Ela Elyada et al.   Cancer Discovery

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

(2019) Wungki Park et al.   BRITISH JOURNAL OF CANCER

Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection

(2019) Hirokazu Kubo et al.   WORLD JOURNAL OF SURGERY

Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy

(2019) Claudia X Dominguez et al.   Cancer Discovery

Inter- and intra-tumoral heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma

(2018) Cindy Neuzillet et al.   JOURNAL OF PATHOLOGY

IL-1-induced JAK/STAT signaling is antagonized by TGF-beta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma

(2018) Giulia Biffi et al.   Cancer Discovery

Targeting both tumour-associated CXCR2+neutrophils and CCR2+macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

(2017) Timothy M Nywening et al.   GUT

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer

(2017) Daniel Öhlund et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells

(2016) Nagaraj S. Nagathihalli et al.   Oncotarget

Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer

(2015) SHINICHIRO HASEGAWA et al.   Oncology Letters

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity

(2014) Ingunn M Stromnes et al.   GUT

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

(2012) S. Banerjee et al.   ANNALS OF ONCOLOGY

Correlation Between the Pretherapeutic Neutrophil to Lymphocyte Ratio and the Pathologic Response to Neoadjuvant Chemotherapy in Patients With Advanced Esophageal Cancer

(2012) Hiroshi Sato et al.   WORLD JOURNAL OF SURGERY